Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.
The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 diabetes and obesity. Recent breakthroughs in research for sleep apnea, polycystic ovarian syndrome, Parkinson’s disease and more have demonstrated their potential.
Twelves
In the coming year, patients will have greater access to these medications than ever before. We’ll see more and more providers integrating GLP-1s into their patients’ treatment plans, indications across various therapeutic areas, and, subsequently, more payers offering coverage for them.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Insights Into Chronic Itch From Shawn Kwatra, M.D.
April 15th 2025A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
Read More